The Dow Chemical Company

Dow Global Technolgoies LLC

Kenneth McMillan

Jaime Simon

David A Wilson

Joseph R Garlich

R Keith Frank

William Jack Kruper, Jr

William A Fordyce

Roberta C Cheng

Garry E Kiefer

Richard Keith Frank

Harrell L Huff

Alan D Strickland

Lance A Cooper

William F Goeckeler

Daniel J Macey

Sharon Braughman

Sharon Baughman

William F Goeckler

Dana W Simon

William F Goeckleler

This invention relates to medical uses of radiopharmaceuticals. Specifically, the present invention relates to the use of radiopharmaceuticals to treat osteomyelitis. The present invention provides improved system and methods of for the direct delivery of radiopharmaceuticals to the site of osteomyelitis.

Treatment of osteomyelitis with radiopharmaceuticals

Radiopharmaceutical formulations for complexes comprising at least one radionuclide complexed with a ligand, or its physiologically-acceptable salts thereof, especially .sup.153 samarium-ethylenediaminetetramethylenephosphonic acid, which optionally contains a divalent metal ion, e.g. calcium, and is frozen, thawed, and then administered by injection.

Frozen radiopharmaceutical formulations

A group conjugates having a functionalized polyaminocarboxylate chelant that form complexes with rare earth-type metal ions, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes.

Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic

A group of functionalized amine chelants having ortho ligating functionality that form complexes with rare-earth type metal ions are disclosed. The complexes can be covalently attached to an antibody or antibody fragment and used for therapeutic and/or diagnostic purposes. In addition certain of the chelant-radionuclide complexes can be effectively employed in compositions useful as therapeutic and/or diagnostic agents for calcific tumors and/or relief of bone pain.

Conjugates possessing ortho ligating functionality

Conjugates possessing ortho ligating functionality and complexes thereof

A group of functionalized polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes.

Macrocyclic ligands and complexes

A group of functionalized macrocyclic polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes for cancer.

Macrocyclic congugates and their use as diagnostic and therapeutic agents

A group of functionalized amine chelants having ortho ligating functionality that form complexes with rare-earth type metal ions are disclosed. The chelants possess the general formula ##STR1## wherein R.sup.'1, R.sup.'2, R.sup.'3, R.sup.'4, R.sup.'5 and R.sup.'6, Z' and X are all defined in the specification. In addition certain of the chelant-radionuclide complexes can be effectively employed in compositions useful as therapeutic and/or diagnostic agents for calcific tumors and/or relief of bone pain.

Complexes possessing ortho ligating functionality

Radioactive compositions containing a calcific matrix and methods for using the compositions for therapeutic radiation treatment including rheumatoid arthritis are disclosed.

Radiolabeled compositions containing a calcific matrix and their use for

A stabilized radionuclide-colloid composition useful in therapeutic radiation ablation therapies is disclosed. The composition contains a viscosity modifier layered mixed metal hydroxide and optionally an ion exchange medium to stabilize the radioactive colloid.

Layered mixed metal hydroxides for the stabilization of radioactive

Radioactive high molecular weight metal-binding protein compositions and a method for therapeutic radiation treatment including the treatment of rheumatoid arthritis comprising injection of a radioactive high molecular weight metal-binding protein compositions are disclosed.

Radiolabeled metal-binding protein for the treatment of arthritis

Radiolabeled colloid compositions and a method for the preparation of radionuclide-colloid compositions useful in the treatment of rheumatoid arthritis are disclosed. A radionuclide selected from the group consisting of Sm-135, Ho-166, In-155m, Y-90, Gd-159 La-140, Lu-177, or Yb-175 is sorbed to a previously prepared iron-hydroxide colloid. The radiolabeled colloid compositions are comprised of spherical aggregations containing greater than 50% of the radioactive metal in iron-hydroxide particles. The method produces stable radionuclide iron-hydroxide compositions which are useful in therapeutic procedures such as radiation synovectomy.

Radiolabeled colloid compositions and method for preparing same

The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, Holmium-166 and Yttrium-90 and at least one macrocyclic aminophosphonic acid ligand containing the 1,4,7,10-tetraazacyclododecane moiety, or a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.

Bone marrow suppressing agents

The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 and 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.

Growing community of inventors

Richwood, TX, United States of America

Kenneth McMillan